Alleviation of gram-negative bacterial lung inflammation by targeting HECTD2

Lung injury remains a significant clinical problem worldwide. The nature and pathogenesis of the injury is highly multifactorial as it can be acute or chronic, triggered by bacteria, viruses, fungi, transfusions, sepsis, multiple fractures, aspiration and several other factors. In the case of invading pathogens and sepsis, the innate immune system may get overwhelmed, resulting in the secretion of large amounts of proinflammatory cytokines which mediate pulmonary edema, shock and potentially, multi-organ failure (1,2).